Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 5, 2017

Myriad introduces new tool to enhance hereditary cancer testing

US-based molecular diagnostics firm Myriad Genetics has introduced a new medical tool, riskScore, to support its myRisk test developed for hereditary cancer.

US-based molecular diagnostics firm Myriad Genetics has introduced a new medical tool, riskScore, to support its myRisk test developed for hereditary cancer.

riskScore is an algorithm designed to combine genetic markers with a patient’s family and clinical history to quantify the risk of breast cancer development.

The tool will combine data from more than 80 genetic markers called single nucleotide polymorphisms (SNPs) throughout the genome with a family and personal history algorithm called Tyrer-Cuzick model.

Myriad Genetics president and CEO Mark Capone said: “Through the years, Myriad has expanded the number of genes tested and demonstrated.

“Now this new test will provide definitive answers to the 90% of patients testing negative for hereditary cancer genes and will be complimentary to patients tested with myRisk.”

"This new test will provide definitive answers to the 90% of patients testing negative for hereditary cancer genes and will be complimentary to patients tested with myRisk."

Researchers at the firm initially optimised the genetic markers in riskScore with more than 100,000 patient samples.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

The researchers subsequently completed two statistically significant validation studies assessing the tool’s ability to predict the risk of breast cancer in European patients.

The Myriad myRisk Hereditary Cancer test is a 28-gene panel that can identify the risk of breast, ovarian, gastric, colorectal, pancreatic, melanoma, prostate and endometrial cancers.

In addition to a risk assessment, the simple and easy-to-use test delivers specific medical management recommendations to patients who test either positive or negative according to the guidelines of select professional medical societies.


Image: Myriad Genetics researchers. Photo: courtesy of Myriad Genetics Inc.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU